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Abstract 
Objectives 
To assess the performance of Ga-PSMA PET for positive lymph nodes on imaging after 
curatively intended radical prostatectomy. 
Patients and methods 
Seventeen patients with biochemical recurrence after radical prostatectomy undergoing 
robot assisted salvage lymphadenectomy for positive lymph nodes on imaging were 
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included in this single surgeon study. The performance of Ga-PSMA PET was assessed 
on a per patient, per lesion, per landing site and per laterality level using sensitivity, 
specificity, negative and positive predictive value analysis. 
Results 
A total of 34 positive nodes were detected on Ga-PSMA PET with a median of 2 nodes per 
patient (IQR 1 - 3 nodes per patient). Sixty six nodes were pathologically disease positive 
from 14 patients, with a median of 2 positive nodes per patient (IQR 1 - 6). Three patients 
had no pathologically detectable disease. On a per patient basis the positive predictive 
value was 82%. Sensitivity, specificity and negative predictive value were not able to be 
calculated as all patients had disease recurrence with a detectable PSA. 
On a “per lesion” basis, the sensitivity, specificity, positive predictive value and negative 
predictive value were 36.7%, 96.9%, 73.5% and 86.7%, respectively. 
Conclusion 
Our study indicates that sensitivity of Ga-PSMA PET in the salvage setting is not yet 
sufficient to detect all sites of metastasis. Therefore, imaging guided metastasis targeted 
treatment is likely to fail given the likely concomitant imaging negative more widespread 
disease. 
 
Keywords: Ga-PSMA PET; Staging; Prostate cancer 
 
Introduction 
Prostate cancer is the most common solid organ malignancy affecting male patients in 
Western populations. Although PSA screening has lead to earlier stage diagnosis in most 
men, a significant number will fail local therapy and suffer biochemical relapse. Ga-PSMA 
PET has emerged as a more sensitive and specific investigation than any other imaging 
modality, generating renewed interest in a theoretical “oligometastatic” state. However, 
there is little data on the sensitivity of Ga-PSMA PET at an individual lesion level, as 
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distinct from overall sensitivity at the patient level. Successful treatment of the 
oligometastatic state is dependent on correctly identifying all metastases in an individual 
patient, otherwise further relapse is inevitable. The aim of this study was to determine the 
individual lesion sensitivity of Ga-PSMA PET in a patient population undergoing salvage 
pelvic lymph node dissection after failed local therapy with curative intent. 
Patients and Methods: 
From April 2015 to August 2017, 17 patients with pelvic and/or retroperitoneal node only 
recurrence on Ga-PSMA PET imaging were included in this prospectively recorded and 
retrospectively analysed single surgeon (PD) study. 
All patients presented with biochemical recurrence (as defined by PSA >0.2ug/l) after 
curative intended radical prostatectomy without extended pelvic lymphadenectomy. All 
patients underwent a Ga-PSMA PET in addition to full body diagnostic computed 
tomography for re-staging. Selected patients with clinical suspicion of local recurrence also 
underwent pelvic magnetic resonance imaging to exclude local pelvic recurrence. Each 
patient was discussed in a dedicated prostate cancer multidisciplinary meeting and were 
deemed suitable for salvage treatment if they had lymph node only recurrent disease 
detected on Ga-PSMA PET imaging and the identified nodes were considered surgically 
resectable. Although all patients were consented to the experimental nature of the 
treatment, there were no patients who declined to undergo surgery. Included patients 
underwent robot assisted salvage pelvic +/- limited retroperitoneal lymph node dissection. 
Three patients had concomitant retroperitoneal node dissection. Only two patients had 
undergone pelvic node dissection at the time of radical prostatectomy (limited obturator 
node dissection in one patient and unilateral node dissection in a second patient), 4 
patients had received and then ceased prior androgen deprivation and four patients had 
received prior salvage external beam radiotherapy. One patient had received stereotactic 
radiotherapy to a pelvic bone metastases at the time of radical prostatectomy and 3 years 
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prior to salvage lymphadenectomy. Patients were followed up with a clinical review one 
week after surgery. PSA was first performed 3 months postoperatively, then every 3 
months. 
Surgery:  
Port placement and robotic arm set-up was identical to that performed for robotic assisted 
radical prostatectomy if extended pelvic lymphadenectomy only was performed. When 
limited retroperitoneal node dissection was performed in conjunction with extended pelvic 
lymphadenectomy, the camera port and arms were placed approximately 7cm proximally. 
All patients underwent a systematic bilateral extended pelvic lymphadenectomy, including 
tissue over the common iliac vessels to the crossing of the ureter, the external iliac vessels 
down to the node of Cloquet, the obturator fossa and the internal iliac vessels. Presacral 
tissue was sent only when suspicious nodes were identified in this region on imaging.  
When Ga-PSMA PET positive lymph nodes were identified in the retroperitoneum, the 
dissection included the tissue over the common iliac arteries and the retroperitoneum, 
bounded by the ureters laterally, to the level of the inferior mesenteric artery. Tissue was 
sent in separate packets from each anatomical region unless the hemi-pelvis was node 
negative on imaging, in which case the tissue was sent as a single packet from that side 
only. When limited retroperitoneal dissection was performed, tissue was sent from the pre-
aortic, paracaval and interaortocaval regions separately. Thirteen landing sites were 
described per patient (Fig. 1). 
Pathologic processing: 
Identified lymph nodes were sampled and processed using routine protocols. Sampled 
nodal tissue was sectioned at 3um and stained with routine H&E. Histopathological 
assessment was performed, with quantification and reporting of total number of nodes, 
number of involved nodes and size of individual deposits. PSMA immunohistochemical 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 5 
staining with Dako 3E6, 1:50 dilution was performed on representative metastatic tumour 
deposits. 
Ga-PSMA PET acquisition: 
Ga68-PSMA-HBED-CC was produced using an IRE Galli Eo 68Ge/68Ga generator with 
Scintomics GRP module. ITLC, HPLC and pH testing was performed to assure radiotracer 
purity. 
Patient dose was 1.3-2.0 MBq/kg, IV 20 mgs Lasix was administered 10 minutes after 
tracer injection, unless significant urinary symptoms were reported. 
During the uptake phase of 60-90 minutes, patients were hydrated orally with water.  
Images were obtained using a Siemens Biograph mCT(20) Excel scanner. 
After voiding, imaging was started with a low dose CT scan acquisition (120 KV, 30-
50mAs, 16x1.2 mm collimation with 1.0 pitch, rotation time of 0.5 for 780 mm FOV for 
attenuation correction) with 3mm slice thickness in 2 mm increments using Siemens CARE 
Dose 4D. 
PET acquisition was performed in the caudocranial direction from mid thighs to vertex with 
3-4 min bed position and dose modulation was used for CT attenuation correction. 
PET slices were reconstructed using iterative reconstruction and TOF (2 iteration/21 
subsets) with a transaxial spatial resolution in the reconstructed PET images of 7.0mm at 
FWHM.  
The lung field was additionally separately reconstructed using a lung kernel and a 
maximum intensity reconstruction.  
Axial sagittal, coronal PET and CT images and fused PET /CT images were reviewed 
using Syngo (Siemens) software for image analysis and interpretation. 
All images were analysed prior to surgery by a certified nuclear medicine radiologist and 
reviewed at a multidisciplinary conference including urologists, radiation and medical 
oncologists, general radiologist and a nuclear medicine radiologist.  
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Statistics:  
Categorical data are presented as counts or percentages. The continuous variables are 
presented with median and interquartile range. The performance of Ga-PSMA PET was 
assessed at the patient level, “per lesion”, by anatomical landing site and by laterality 
using sensitivity, specificity, positive predictive value and negative predictive value.  
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software Inc.). 
Results: 
Patient characteristics at the time of radical prostatectomy and at the time of salvage 
lymph node dissection are presented in table 1. Sixteen of seventeen patients had node 
only recurrence detected on Ga-PSMA PET and 1/17 patient had node only recurrence on 
computed tomography with negative Ga-PSMA PET imaging. The median PSA pre-
operatively was 1.6ng/mL (IQR 0.81 - 2.70ng/mL) with a median PSA doubling time of 
4.85 months (IQR 3.55 - 7.2 months). A total of 34 positive nodes were detected on Ga-
PSMA PET with a median of 2 nodes per patient (IQR 1 - 3 nodes per patient). The 
median time from radical prostatectomy to salvage node dissection was 4 years.  
A total of 356 nodes were removed from 17 patients with a median node count of 20 
nodes per patient (IQR 14 - 25). Sixty six nodes were pathologically disease positive from 
14 patients, with a median of 2 positive nodes per patient (IQR 1 - 6). The average node 
deposit was 7.92mm (range 0.7 - 28mm). Three patients had no pathologically detectable 
disease; two of these patients had 1 Ga-PSMA PET avid node and one patient had 2 Ga-
PMSA PET avid nodes. One patient had a PET positive mesorectal node that was 
unresectable and a further patient had a deep internal iliac node that was unresectable. 
Both patients had post-operative Ga-PSMA PET confirming the persisting presence of 
respective nodes.  
The median size of Ga-PSMA PET positive node deposits was 10mm in comparison to 
4mm for Ga-PSMA PET negative node deposits (p=0.0026). The smallest node deposit 
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detected on Ga-PSMA PET was 4.5mm whilst the smallest node deposit resected was 
0.7mm. 
On a per patient basis the positive predictive value was 82%. One patient was considered 
true positive without histologic correlation as they had an unresectable internal iliac node 
that had persisting Ga-PSMA PET avidity post-operatively. This patient was subsequently 
treated with stereotactic radiotherapy to the internal iliac node, which resulted in a PSA 
decline from 1.2ng/mL to 0.194ng/mL. Sensitivity, specificity and negative predictive value 
were not able to be calculated for this cohort of patients as there were no true negative 
patients who underwent surgery and by definition, all patients had disease recurrence with 
a detectable PSA following primary extirpative treatment.  
On a “per lesion” basis, the sensitivity, specificity, positive predictive value and negative 
predictive value were 36.7%, 96.9%, 73.5% and 86.7%, respectively. When each of the 13 
nodal basins were considered rather than each individual node in isolation, sensitivity and 
negative predictive value improved to 64.7% and 92.9% respectively, but specificity and 
positive predictive value were slightly worse at 94.0% and 68.8%. When results were 
considered by laterality only (i.e. right versus left), sensitivity and positive predictive value 
improved again at 86.9% and 83.3%, but this was at the expense of specificity and 
negative predictive value at 66.7% and 72.7% respectively.  
Discussion: 
There has been increasing interest in metastasis directed therapy in patients presenting 
with limited metastatic burden either at the time of primary therapy, or in patients 
presenting with disease recurrence following definitive primary therapy. Both surgical 
extirpation and stereotactic radiotherapy have been utilised in this context, but surgery has 
been reserved only for patients presenting with lymph node only recurrences. Although 
long term biochemical recurrence free survival is possible following oligometastatic 
treatment, the majority of patients suffer biochemical recurrence and many progress to 
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clinical recurrence. Such an approach is clearly dependent on the sensitivity of imaging to 
detect all recurrences in an individual patient in order that they can be treated. Traditional 
staging for prostate cancer patients has included computed tomography, MRI and Tc-
labelled whole body bone scan. Each of these investigations have poor sensitivity, 
particularly in patients with low PSA values. More recently, choline and fluorocholine PET 
have been utilised for staging, particularly in the setting of disease recurrence, but 
sensitivity is low, especially in patients with PSA values <1.0ng/mL1,2. 
Ga-PSMA PET has emerged over the last few years as a highly sensitive and specific 
investigation, particularly in the setting of biochemical recurrence following definitive 
primary treatment and even with very low PSA. An original report by Afshar-Oremieh et al 
in 2014 on the diagnostic performance of Ga-PSMA PET in 319 patients indicated very 
high sensitivity and specificity, even in patients with very low PSA values3. Histopathologic 
correlation, however, was obtained in very few patients. Their update in over 1000 patients 
reported similarly high sensitivity, but again without histopathologic correlation in most 
patients4. Maurer et al reported on 130 patients with primary staging PSMA PET yielding a 
sensitivity of 65.9% based on template extended pelvic lymphadenectomy and a specificity 
of 98.9%, but they reported on the diagnostic performance at the patient level and not the 
individual lesion level5. The same group published on histopathologic correlation in the 
salvage setting, with field based sensitivity 77.9% and PPV 94.6%6. However, only 11 of 
48 patients received an extended template based lymphadenectomy, with the remaining 
undergoing node dissection based on pre-operative imaging, which leaves the possibility 
of undetected metastatic disease in remaining lymph node fields.  
Other groups have reported on histopathologic correlation with pre-operative PSMA 
imaging. Jilg et al reported a sensitivity 93.2% and PPV of 100% on the basis of “main 
regions” (left and right hemipelvis and retroperitoneum). On a subregion basis however, in 
which each hemipelvis was divided into 5 commonly used anatomical descriptors and the 
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retroperitoneum divided into 4 subregions, sensitivity fell to 81.2% but PPV remained high 
at 99.5%7. In their series, only 24/30 patients underwent a full bilateral tempate 
lymphadenectomy. In a comparison of FEC and Ga-PSMA PET, Pfister et al performed a 
systematic template based lymphadenectomy, but it is not clear if bilateral template 
dissection was performed8. They report sensitivity of 86.9% on a “per lesion” basis, but of 
note, a mean of only 11 lymph nodes were removed per patient.  
Most reports on the sensitivity of Ga-PSMA PET are at the population level. This may be 
useful for patients considering salvage radiotherapy for example, where the presence of 
metastatic disease may render this approach futile9. However, when considering an 
aggressive oliometastatic approach, an inability to identify all individual lesions within a 
given patient will lead to biochemical persistence post treatment. The “per lesion” 
sensitivity is therefore a much more useful reference. Only two other studies that we could 
identify reported on the “per lesion” sensitivity of Ga-PSMA PET following pelvic 
lymphadenectomy10,11. In both of these studies, the sensitivity was higher than what we 
report, but the average number of nodes resected per patient was 12 and 12.6 
respectively. Indeed, one of these studies also included retroperitoneal node dissection to 
a testis cancer template10. This compares to a median lymph node yield of 20 per patient in 
the current study. The low lymph node yield in these previous studies may reflect an 
incomplete pelvic lymphadenectomy, or it may be because of prior primary 
lymphadenectomy. In the setting of incomplete lymphadenectomy, the sensitivity is likely 
to be overestimated. Alternatively, prior lymphadenectomy may improve the diagnostic 
accuracy of Ga-PSMA PET because of a lower node density and fewer potential drainage 
sites. It is interesting to note that both of the studies assessing diagnostic accuracy of Ga-
PSMA PET in the primary setting (at which time all patients have an intact pelvic nodal 
basin), showed a lower sensitivity in comparison to studies assessing diagnostic accuracy 
of Ga-PSMA PET in the salvage setting5,7,10-14.  
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The smallest node deposit detected by Ga-PSMA PET in the current study was 4.5mm. 
This is almost identical to that reported by Budaus et al, in which the limit of detection of 
Ga-PSMA PET was 4mm12. The median node deposit in Ga-PSMA PET positive and 
negative metastases was 13.6 and 4.3mm, similar to the current study12. It would appear 
then, that the limit of detection of nodal disease on Ga-PSMA PET imaging is around 
4mm, which would explain why most patients suffer biochemical recurrence following 
oligometastatic treatment. It is not known if the limit of detection is the same for bone 
metastases, but it would seem logical that there is a similar limit of detection. 
Another consideration in the assessment of imaging performance is that of inter-interpreter 
variation. Maximum standardised uptake values (SUVmax) are higher with Ga-PSMA PET 
in comparison to FEC PET, which allows lesions to be seen more clearly and is likely to 
reduce inter-interpreter variation3. However, even on Ga-PSMA PET, some lesions may be 
weakly avid and therefore difficult to characterise. To our knowledge there is no data about 
inter-interpreter variation in the reporting of PSMA PET scans in the salvage setting for 
prostate cancer. 
Conclusion 
Although Ga-PSMA PET has shown superior diagnostic accuracy than other imaging 
modalities in prostate cancer, the current study indicates that the sensitivity is not yet 
sufficient to detect all sites of metastasis in most patients. These findings need to be 
considered in patients undergoing metastasis directed treatment given that imaging 
negative and therefore untreated metastasis might negatively influence the outcome. 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 11 
References 
1. Castellucci P, Ceci F, Graziani T, et al. Early biochemical relapse after radical 
prostatectomy: which prostate cancer patients may benefit from a restaging 11C-
Choline PET/CT scan before salvage radiation therapy? J Nucl Med. 
2014;55(9):1424-1429. doi:10.2967/jnumed.114.138313. 
2. Van den Bergh L, Lerut E, Haustermans K, et al. Final analysis of a prospective trial 
on functional imaging for nodal staging in patients with prostate cancer at high risk 
for lymph node involvement. Urologic Oncology: Seminars and Original 
Investigations. 2015;33(3):109.e23-109.e31. doi:10.1016/j.urolonc.2014.11.008. 
3. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging 
with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate 
cancer. Eur J Nucl Med Mol Imaging. 2014;42(2):197-209. doi:10.1007/s00259-014-
2949-6. 
4. Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 
68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: 
evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258-1268. 
doi:10.1007/s00259-017-3711-7. 
5. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of 68Gallium-PSMA 
Positron Emission Tomography Compared to Conventional Imaging for Lymph Node 
Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. 
J Urol. 2016;195(5):1436-1443. doi:10.1016/j.juro.2015.12.025. 
6. Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the 
Assessment of Lymph Node Metastases in Prostate Cancer Patients with 
Biochemical Recurrence: Comparison with Histopathology After Salvage 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 12 
Lymphadenectomy. Journal of Nuclear Medicine. 2016;57(11):1713-1719. 
doi:10.2967/jnumed.116.173492. 
7. Jilg CA, Drendel V, Rischke HC, et al. Diagnostic Accuracy of Ga-68-HBED-CC-
PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent 
Prostate Cancer. Theranostics. 2017;7(6):1770-1780. doi:10.7150/thno.18421. 
8. Pfister D, Porres D, Heidenreich A, et al. Detection of recurrent prostate cancer 
lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-
CC than with 18F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging. 
2016;43(8):1410-1417. doi:10.1007/s00259-016-3366-9. 
9. Emmett L, Van Leeuwen P, Nandurkar R, et al. Treatment outcomes from 
68GaPSMA PET CT informed salvage radiation treatment in men with rising PSA 
following radical prostatectomy: Prognostic value of a negative PSMA PET. Journal 
of Nuclear Medicine. July 2017:jnumed.117.196683–22. 
doi:10.2967/jnumed.117.196683. 
10. Pfister D, Porres D, Heidenreich A, et al. Detection of recurrent prostate cancer 
lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-
CC than with 18F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging. 
2016;43(8):1410-1417. doi:10.1007/s00259-016-3366-9. 
11. Hijazi S, Meller B, Leitsmann C, et al. Pelvic lymph node dissection for nodal 
oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission 
tomography/computerized tomography. Prostate. 2015;75(16):1934-1940. 
doi:10.1002/pros.23091. 
12. Budäus L, Leyh-Bannurah S-R, Salomon G, et al. Initial Experience of 68Ga-PSMA 
PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 13 
Prostatectomy. European Urology. 2016;69(3):393-396. 
doi:10.1016/j.eururo.2015.06.010. 
13. Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the 
Assessment of Lymph Node Metastases in Prostate Cancer Patients with 
Biochemical Recurrence: Comparison with Histopathology After Salvage 
Lymphadenectomy. Journal of Nuclear Medicine. 2016;57(11):1713-1719. 
doi:10.2967/jnumed.116.173492. 
14. Herlemann A, Wenter V, Kretschmer A, et al. 68Ga-PSMA Positron Emission 
Tomography/Computed Tomography Provides Accurate Staging of Lymph Node 
Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. European 
Urology. 2016;70(4):553-557. doi:10.1016/j.eururo.2015.12.051. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 14 
Table 1) Patient characteristics 
At time of radical prostatectomy  
Median age, years (IQR) 66 (60-70) 
Median follow up, months (IQR) 27 (9-37) 
Pathological Gleason Score, n  
3+4 1 
4+3 6 
4+4 6 
4+5 4 
Pathological T stage, n  
pT2a 1 
pT2c 3 
pT3a 7 
pT3b 6 
Margin status, n  
negative 12 
positive 5 
Salvage Radiotherapy, n  
No 13 
Yes 4 
ADT before salvage LND, n  
No 13 
Yes 4 
  
At time of salvage lymph node dissection   
Median age, years (IQR) 69 (67-75) 
Median time from RP to sLND, years (IQR) 4 (1.5-8) 
Median positive nodes on Ga-PSMA-PET, n 
(IQR) 
2 (1-3) 
Median pathologically positive LND, n (IQR)  
Extracapsular extension (n) 2 (1-6) 
10  
ADT: androgen deprivation therapy; (s)LND: (salvage) lymph node dissection; RP: radical 
prostatectomy 
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